Overview

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Status:
Active, not recruiting
Trial end date:
2026-06-28
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Clovis Oncology, Inc.
Genentech, Inc.
Treatments:
Antibodies, Monoclonal
Atezolizumab
Bevacizumab
Rucaparib